Form 4: Ionis Pharmaceuticals Director Exercises Stock Options Nearing Expiration
SEC Form 4
Director Joseph H. Wender exercised stock options for 16,000 shares of Ionis Pharmaceuticals (IONS) nearing their expiration date.
Summary
- On May 9, 2024, Joseph H. Wender, a director of Ionis Pharmaceuticals, exercised non-qualified stock options to acquire 16,000 shares of common stock.
- The exercise price was $35.53 per share.
- The options were set to expire on June 30, 2024.
- Following the transaction, Wender beneficially owns 128,079 shares indirectly through a trust.
- The stock option was originally granted on July 1, 2015.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option exercise.
Industry Context
This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction may have a minor dilutive effect on existing shareholders due to the issuance of new shares.
Key Dates
| Date | Description |
|---|---|
| 07/01/2015 | Date the non-qualified stock options were granted. |
| 05/09/2024 | Date of transaction: Director exercised stock options. |
| 06/30/2024 | Expiration date of the stock options. |
| 05/13/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.